2-氧代-6-苯基-1,2-二氢-3-吡啶羧酸 | 56162-63-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氧代-6-苯基-1,2-二氢-3-吡啶羧酸
• 中文别名: 2-氧代-6-苯基-1,2-二氢吡啶-3-羧酸
• 英文名称: 2-oxo-6-phenyl-1,2-dihydropyridine-3-carboxylic acid
• 英文别名: 2-oxo-6-phenyl-1H-pyridine-3-carboxylic acid
• CAS: 56162-63-1
• 化学式: C₁₂H₉NO₃
• mdl: MFCD01105052
• 分子量: 215.208
• InChiKey: MHFTTYLYTCCJGW-UHFFFAOYSA-N

物化性质

• 溶解度：
  >32.3 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  2-氧代-6-苯基-1,2-二氢-3-吡啶羧酸 在 二苯基磷酸 、 sodium methylate 、 sodium hydride 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 反应 46.25h， 生成 2-(3-amino-2-oxo-6-phenyl-1,2-dihydro-1-pyridyl)-N-<2-<(tert-butyldimethylsilyl)oxy>-3,3,3-trifluoro-1-isopropylpropyl>acetamide
  参考文献：
  名称：

  Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis, and in vitro Activity of a Series of 3-Amino-6-aryl-2-oxopyridyl Trifluoromethyl Ketones

  摘要：

  A series of potent nonpeptidic inhibitors of the enzyme human leukocyte elastase (HLE) is reported. These inhibitors contain a 3-amino-2-pyridone ring as a central template in which the pyridone carbonyl and 3-position NH group are thought to form important hydrogen bonding interactions with the Val-216 residue of HLE. Substitution of the 6-position of the pyridone ring by various alkyl and aryl groups was found to afford increases in the in vitro potency of these inhibitors. A 6-position phenyl group, compound 10f, was found to result in a large increase in binding affinity, which was not obtained when the phenyl group was placed in either the 4- or 5-position of the molecule. Compound 10f was found to have good selectivity for HLE over other proteolytic enzymes, with the exception of bovine pancreatic chymotrypsin (BPC). Substitution of the 6-phenyl group in these molecules was found to decrease binding affinity for BPC without adversely affecting affinity for HLE.

  DOI：

  10.1021/jm00046a015
• 作为产物：
  描述：

  Methyl 1,2-Dihydro-2-oxo-6-phenyl-3-pyridinecarboxylate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 5.0h， 生成 2-氧代-6-苯基-1,2-二氢-3-吡啶羧酸
  参考文献：
  名称：

  铑催化的2-吡啶酮的C4选择性C–H烯基化（无痕导向组策略）

  摘要：

  已经开发了铑催化的3-羧基-2-吡啶酮与苯乙烯的C4-选择性CH烯基化反应。C3位置的羧基用作无痕导向基团，相应的C4-烯基化2-吡啶酮仅通过伴随脱羧作用获得。与报道的方法不同，即使在C5和C6位置可能存在更具反应性的C–H键的情况下，也可以一致地观察到独有的C4选择性。通过使用这种策略，可以通过连续的C–H官能化反应制备多取代的2-吡啶酮。

  DOI：

  10.1021/acs.orglett.1c00050

文献信息

• Base-catalysed ¹⁸F-labelling of trifluoromethyl ketones. Application to the synthesis of ¹⁸F-labelled neutrophil elastase inhibitors
  作者：Denise N. Meyer、Miguel A. Cortés González、Xingguo Jiang、Linus Johansson-Holm、Monireh Pourghasemi Lati、Mathias Elgland、Patrik Nordeman、Gunnar Antoni、Kálmán J. Szabó

  DOI：10.1039/d1cc03624f

  日期：——

  A new method for the fluorine-18 labelling of trifluoromethyl ketones has been developed. This method is based on the conversion of a–COCF3 functional group to a difluoro enol silyl ether followed by halogenation and fluorine-18 labelling. The utility of this new method was demonstrated by the synthesis of fluorine-18 labelled neutrophil elastase inhibitors, which are potentially useful for detection

  开发了一种用于三氟甲基酮的氟 18 标记的新方法。该方法基于将 a-COCF 3官能团转化为二氟烯醇甲硅烷基醚，然后进行卤化和氟 18 标记。氟 18 标记的中性粒细胞弹性蛋白酶抑制剂的合成证明了这种新方法的实用性，这些抑制剂可能用于检测炎症性疾病。
• Heterocyclic amides
  申请人：Zeneca Limited

  公开号：US05521179A1

  公开（公告）日：1996-05-28

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新颖的杂环酰胺，它们是式I所示的1-吡啶乙酰胺化合物，这些化合物是人类白细胞弹性蛋白酶（HLE）的抑制剂，也被称为人类中性粒细胞弹性蛋白酶（HNE），使它们在需要这种抑制作用时非常有用，例如用作药理学、诊断和相关研究工具以及治疗哺乳动物中HLE相关疾病。该发明还包括在合成这些杂环酰胺过程中有用的中间体，制备这些杂环酰胺的方法，含有这些杂环酰胺的药物组合物以及它们的使用方法。
• [EN] THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] DÉRIVÉS DE THIÉNOPYRIDINE ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
  申请人：WELLMARKER BIO CO LTD

  公开号：WO2019182274A1

  公开（公告）日：2019-09-26

  A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions comprising same can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.

  由化学式1表示的噻吩吡啶衍生物化合物或其药用盐在蛋白激酶活性上具有出色的抑制作用，因此，包含该化合物的药物组合物可用于预防或治疗与蛋白激酶活性相关的疾病。
• Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US06133258A1

  公开（公告）日：2000-10-17

  Neuroprotective agents based on inhibition of kainic acid neurotoxicity and compounds useful as neuroprotective agents based on inhibition of kainic acid neurotoxicity. An inhibitors of kainic acid neurotoxicity, comprising as an active ingredient a pyridothiazine derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof, and a pyridothiazine derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein symbols in the formula have the following respective meanings: the ring A: a pyridine ring; ##STR2## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 may be the same or different and each represent a hydrogen atom or a lower alkyl, cycloalkyl, alkenyl, aryl, carboxyl or lower alkoxycarbonyl group which may have substituent(s), or are not present, with the proviso that R.sup.2 and R.sup.3 may together form a nitrogen-containing heterocyclic group which may have nitrogen atoms as another hetero atom, may be fused with a benzene ring and may have a lower alkyl group as a substituent.

  基于抑制kainic酸神经毒性的神经保护剂和作为神经保护剂的化合物。一种kainic酸神经毒性抑制剂，包括以下通式(I)所代表的吡啶噻嗪衍生物或其药学上可接受的盐作为活性成分，以及以下通式(I)所代表的吡啶噻嗪衍生物或其药学上可接受的盐：##STR1## 公式中的符号具有以下各自的含义：环A：吡啶环；##STR2## R.sup.1、R.sup.2、R.sup.3、R.sup.4和R.sup.5可以相同也可以不同，每个代表氢原子或较低的烷基、环烷基、烯烃基、芳基、羧基或较低的烷氧羰基基团，这些基团可能带有取代基，或者不存在，但需注意R.sup.2和R.sup.3可以共同形成含氮的杂环基团，该基团可能含有氮原子作为另一种杂原子，可能与苯环融合，并且可能具有较低的烷基基团作为取代基。
• Enaminones as Building Blocks in Heterocyclic Syntheses: Reinvestigating the Product Structures of Enaminones with Malononitrile. A Novel Route to 6-Substituted-3-Oxo-2,3-Dihydropyridazine-4-Carboxylic Acids
  作者：Abdul-Aziz Alnajjar、Mervat Mohammed Abdelkhalik、Amal Al-Enezi、Mohamed Hilmy Elnagdi

  DOI：10.3390/molecules14010068

  日期：——

  products of enaminones with malononitrile in ethanolic piperidine are revised. A novel route to 2,3-dihydropyridazine-4-carboxylic acids 4a-c via reactions of 2-cyano-5-(dimethylamino)-5-arylpenta-2,4-dienamides 8a-c with nitrous acid or with benzenediazonium chloride is reported. Compounds 8a-c are converted to 1,2-dihydropyridine-3-carboxylic acid and 1,2-dihydropyridine-3-carbonitrile derivatives upon

  对烯胺酮与丙二腈在乙醇哌啶中反应产物的结构进行了修订。通过 2-cyano-5-(二甲氨基)-5-arylpenta-2,4-dienamides 8a-c 与亚硝酸或与重氮苯氯化物反应获得 2,3-二氢哒嗪-4-羧酸 4a-c 的新途径是报道。化合物8a-c在EtOH/HCl和AcOH中回流时转化为1,2-二氢吡啶-3-羧酸和1,2-二氢吡啶-3-甲腈衍生物。